Navigation Links
Wyeth Provides Regulatory Update on Prevnar 13* in the United States
Date:8/11/2009

sible for the greatest remaining burden of invasive disease. Prevnar has been available in the U.S. for more than nine years. It is currently available in 95 countries and more than 235 million doses have been distributed worldwide.

The Prevnar 13 submission is based on a clinical trial program of 13 core Phase 3 studies involving more than 7,000 infants and young children. To date, the company has submitted regulatory applications for Prevnar 13 in more than 50 countries spanning six continents, with filings in additional countries planned. In July, Prevenar 13*, as it is known outside the U.S., was approved in Chile for use in infants and young children.

About Pneumococcal Disease

Pneumococcal disease is complex and describes a group of illnesses all caused by the bacterium Streptococcus pneumoniae. Pneumococcal disease is the leading cause of vaccine-preventable death worldwide in children younger than 5 years of age and is estimated to cause up to one million deaths worldwide in children each year.

Pneumococcal disease affects both children and adults, and includes invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media.

Important Safety Information for Prevnar 13*

In clinical studies, the most commonly reported adverse events in children were injection site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep. Risks are associated with all vaccines, including Prevnar 13. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. As with any vaccine, Prevnar 13 may not provide 100% protection against vaccine serotypes or protect against nonvaccine serotypes.

Indication for Prevnar((R))

Prevnar(R) is indicated for act
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Wyeth Announces Holder Right to Surrender Convertible Debentures
4. Wyeth Declares Common Stock Dividend
5. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
6. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
7. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
8. Wyeth Declares Common and Preferred Stock Dividends
9. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
10. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
11. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... December 19, 2014 In contrast to ... LEDs with various colors, Valoya uses proprietary LED technology ... offers best possible uniformity which is critical in low ... high spectral accuracy throughout its lifetime which is up ... tubes. , "The investment cost was clearly higher ...
(Date:12/19/2014)... 2014 Egenix, Inc. is pleased to announce that ... the Board, to succeed Donald Fresne ; Mr. Fresne ... as a member of the Board.  In recognition of the ... company over almost twenty years, the Board designated Mr. Fresne ... has established a Search Committee to find a suitable replacement ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... Committee Recommendation in European UnionSAN MATEO, Calif., March 19 ... biopharmaceutical company focused on developing and commercializing novel pain ... call on Friday, March 20, 2009 at 9:00 a.m. ... year-end 2008 results and the European Medicines Agency,s (EMEA) ...
... Solutions, a global life sciences technology solutions company ... that one of the world,s largest pharmaceutical companies ... System. This system provides a powerful, flexible ... lifecycle... from proposal to publication... helping to ensure ...
... will allow the recycling and conversion of 60% ... 19 /PRNewswire/ - Enerkem Inc., a leading advanced ... its plans to build and operate a second-generation ... In addition, the company announced the signature of ...
Cached Biology Technology:NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 2NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 3NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update 4Top Ten Pharma Company Deploys MedNet Solutions' Investigator Initiated Trial Management System 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 3
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... release is available in German . ... and oxygen in order to survive. For this reason, a tumour ... to the blood circulation. In doing this, it is supported by ... neutrophils, which are supposed to protect the body against pathogens. ...
... poisoning in the news, including a recent event that led ... drives home the need for better bacterial detection long before ... the horizon is a new approach for pathogen screening that ... the technique in the ACS journal Analytical Chemistry . ...
... Nutrition Research Centre (CNRC) -- a $20 million ... (A*STAR) and National University Health Systems (NUHS) -- ... conduct nutritional studies to understand the causes of metabolic ... and formulate diets that can reduce the risks of ...
Cached Biology News:Jamming in tumors 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 2Asia's first under-1-roof Nutritional Research Centre set up in Singapore 3Asia's first under-1-roof Nutritional Research Centre set up in Singapore 4
... Peptide microarrays containing peptidomimetics built on ... on-chip synthesis platform. These microarrays are ... Custom Peptide Microarray Service. ... is completely customer specified. Thousands of ...
... are custom designed to meet your needs. ... 8,455 features per array (2 arrays/1" x ... array (1 array/slide). Features ... - This extended length delivers higher sensitivity ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... Chemicon Select Tissue Arrays are intended for ... tissues were fixed in neutral buffered formalin ... and diagnosis was performed by certified pathologists. ... paraffin blocks and relocated into a new ...
Biology Products: